Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
Treatment with CAN-3110 in arm A showed encouraging median overall survival rate at 11.8 months after a single injection. These...